These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37737714)

  • 1. Meta-analysis of primary care delivered buprenorphine treatment retention outcomes.
    Cooper RL; Edgerton RD; Watson J; Conley N; Agee WA; Wilus DM; MacMaster SA; Bell L; Patel P; Godbole A; Bass-Thomas C; Ramesh A; Tabatabai M
    Am J Drug Alcohol Abuse; 2023 Nov; 49(6):756-765. PubMed ID: 37737714
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
    Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
    J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
    Hochheimer M; Unick GJ
    Addict Behav; 2022 Jan; 124():107113. PubMed ID: 34543869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
    Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
    Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
    Degenhardt L; Clark B; Macpherson G; Leppan O; Nielsen S; Zahra E; Larance B; Kimber J; Martino-Burke D; Hickman M; Farrell M
    Lancet Psychiatry; 2023 Jun; 10(6):386-402. PubMed ID: 37167985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
    Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
    J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
    Haddad M; Coman E; Bifulco L
    Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.